Concordance of HER2-low scoring in breast carcinoma among expert pathologists in the United Kingdom and the republic of Ireland –on behalf of the UK national coordinating committee for breast pathology-Reference-Cited by-同舟云学术

Concordance of HER2-low scoring in breast carcinoma among expert pathologists in the United Kingdom and the republic of Ireland –on behalf of the UK national coordinating committee for breast pathology

Published:2023-08 Issue: Volume:70 Page:82-91
ISSN:0960-9776
Container-title:The Breast
language:en
Short-container-title:The Breast

Author:

Zaakouk Mohamed,Quinn Cecily,Provenzano Elena,Boyd Clinton,Callagy Grace,Elsheikh Soha^ORCID,Flint Joe,Millican-Slater Rebecca,Gunavardhan Anu,Mir Yasmeen,Makhija Purnima,Di Palma Silvana,Pritchard Susan,Tanchel Bruce,Rakha Emad,Atallah Nehal M.,Lee Andrew H.S.^ORCID,Pinder Sarah^ORCID,Shaaban Abeer M.^ORCID

Publisher

Elsevier BV

Subject

General Medicine,Surgery

Reference33 articles.

1. HER2-low breast cancer: novel detections and treatment advances;Wu;Crit Rev Oncol Hematol,2023

2. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update;Wolff;J Clin Oncol : official journal of the American Society of Clinical Oncology,2013

3. Human epidermal growth factor receptor 2 testing in breast cancer: American society of clinical oncology/college of American pathologists clinical practice guideline focused update;Wolff;Arch Pathol Lab Med,2018

4. Trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer;Modi;N Engl J Med,2022

5. Enhertu (trastuzumab deruxtecan) an overview of Enhertu and why it is authorised in the EU,2023

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Challenges and improvements in HER2 scoring and histologic evaluation: insights from a national proficiency testing scheme for breast cancer diagnosis in China;Breast Cancer Research;2024-09-03

2. Development and Validation of a HER2-Low Focused Immunohistochemical Scoring System With High-Interobserver Concordance: The Australian HER2-Low Breast Cancer Concordance Study;Modern Pathology;2024-08

3. Analysis of HER2-low breast cancer in Aotearoa New Zealand: a nationwide retrospective cohort study;2024-07-11

4. Pathological Changes Following Neoadjuvant Endocrine Therapy (NAET): A Multicentre Study of 391 Breast Cancers;International Journal of Molecular Sciences;2024-07-05

5. Morphological and molecular changes of oestrogen receptor‐positive breast cancer following bridging endocrine therapy: a United Kingdom multicentre study;Histopathology;2024-06-07